Group 1 - The company signed an exclusive licensing agreement with Kalexo Bio, Inc. for the 2MW7141 project, which includes a total potential payment of up to $1 billion, consisting of upfront and milestone payments, as well as low single-digit royalties [2][5][11] - The agreement is expected to positively impact the company's future performance and enhance its profitability [3][11] - The 2MW7141 project is a dual-target small nucleic acid drug in the preclinical stage, aimed at regulating blood lipids and preventing high-risk cardiovascular events [6][7] Group 2 - The licensing agreement allows Kalexo exclusive rights for the global development, production, and commercialization of the licensed product [8] - The agreement includes a one-time, non-refundable upfront payment of $12 million in cash, and the company will also receive a total of double-digit A-round preferred shares from Kalexo under certain conditions [2][8] - The agreement is governed by New York law and interpreted according to California law [9] Group 3 - The company aims to leverage the collaboration with Kalexo to provide innovative treatment options for global patients, enhancing its brand value and international influence [11] - The agreement will not change the company's main business or operational scope and will not affect its independence [11]

Group 1 - Maiwei Biotech signed an exclusive licensing agreement with Kalexo Bio, potentially receiving up to $1 billion in upfront and milestone payments, along with low single-digit royalties [2] - The agreement allows Kalexo to exclusively develop, manufacture, and commercialize the 2MW7141 project, a dual-target small nucleic acid drug aimed at lipid regulation and cardiovascular event prevention [2] - The deal is expected to positively impact Maiwei's future performance and enhance profitability [2] Group 2 - China Ping An completed the purchase of 74.615 million H shares under its 2025 long-term service plan, accounting for 0.412% of the total share capital, with a total transaction value of 3.875 billion yuan [3] - The average transaction price was approximately 51.87 yuan per share, with 83,024 core talents voluntarily participating in the plan [3] - The holding ratio of directors, supervisors, and senior management in the plan is 2.52%, while other employees hold 97.48% [3] Group 3 - Top Group's actual controller and vice chairman decided to terminate their share reduction plan early, having reduced their holdings by a total of 349.36 million shares, or 0.201% of the total shares [4] - The early termination was due to the fulfillment of their personal funding needs [4] Group 4 - Haon Electric stated that its order amounts are based on customer sales forecasts, and actual order amounts may vary due to market changes [5] - The company is primarily engaged in the development, design, manufacturing, and sales of automotive intelligent driving perception systems, while its robotics business is still in the R&D stage [5] Group 5 - Pinming Technology announced a stock suspension due to planning a significant matter that may lead to a change in control [6][7] - The stock will be suspended for no more than two trading days, with timely announcements to follow regarding the matter's progress [7] Group 6 - Tianpu Co. completed its stock trading suspension investigation and will resume trading on September 18, 2025, after a period of price increases and abnormal trading [8] - The investigation confirmed that there are no asset injection plans from the rumored acquirer, Zhonghaoxin [8] Group 7 - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, secured exclusive agency rights for three products in mainland China from Denmark's ALK-Abelló A/S [9] - Jinsai will pay an upfront fee of 32.7 million euros and additional milestone payments based on regulatory approval and sales performance [9]

Core Viewpoint - The company, Maiwei Biotech, announced plans to engage in foreign exchange derivative trading to mitigate risks associated with foreign exchange market fluctuations, with a total trading limit of up to $50 million or equivalent in other currencies [2] Group 1: Trading Strategy - The company and its subsidiaries intend to use self-owned funds for foreign exchange derivative trading, which includes but is not limited to foreign exchange forwards, swaps, options, and structured forwards [2] - The trading counterparties will be large domestic banks and financial institutions that are approved by regulatory authorities and have a solid credit rating [2] Group 2: Trading Limit and Duration - The total trading limit for foreign exchange derivatives is set at a maximum of $50 million [2] - The validity period for the authorized trading limit is 12 months from the date of approval by the company's board of directors, and the limit can be used in a rolling manner within this timeframe [2]

Group 1: Fiscal Revenue and Budget - In the first eight months of 2025, the national general public budget revenue reached 148198 billion yuan, showing a year-on-year growth of 0.3% [1] - Tax revenue amounted to 121085 billion yuan, with a slight increase of 0.02% year-on-year, while non-tax revenue was 27113 billion yuan, growing by 1.5% [1] - Central government budget revenue was 64268 billion yuan, reflecting a year-on-year decline of 1.7%, whereas local government budget revenue was 83930 billion yuan, increasing by 1.8% [1] Group 2: Smart Connected Vehicles - The Ministry of Industry and Information Technology is soliciting public opinions on mandatory national standards for smart connected vehicle combination driving assistance systems [2] - The proposed standards aim to establish a safety baseline for smart connected vehicle products, requiring systems to activate only under designed operating conditions [2] - The standards include comprehensive safety technical requirements covering human-machine interaction, functional safety, information security, and data recording, creating a "triple safety guarantee" [2] Group 3: Service Consumption Policies - The Ministry of Commerce plans to introduce a series of specialized documents to promote high-quality development in the accommodation industry and the integration of railways and tourism [3] - Over 30 policies have already been implemented to establish a "1+N" policy system for service consumption [3] Group 4: Financial Support for Consumption - The People's Bank of China is actively supporting qualified financial institutions to issue financial bonds and credit asset-backed securities to enhance consumer credit supply capacity [4] - From January to July this year, automotive financial companies issued financial bonds totaling 215 billion yuan and credit asset-backed securities amounting to 484 billion yuan [4] Group 5: Corporate News - Shanghai Construction Group reported that its gold business revenue constitutes a low proportion of total operating income [6] - NIO received an investment of 1.16 billion USD [6] - New materials company plans to reduce its stake by no more than 2% [6] - Huazhu Group intends to invest up to 10 billion yuan in financial products [6] - Several companies, including Maimai Bio and Xinyuan Technology, are involved in significant partnerships and developments [6]

证券日报网讯 9月17日晚间，迈威生物发布公告称，公司与KalexoBio，Inc.公司（简称"Kalexo"）就 2MW7141项目相关（简称"许可产品"）签署《独家许可协议》（简称"许可协议"）及《优先股股权购 买协议》（简称"股权购买协议"）。根据许可协议和股权购买协议，迈威生物许可Kalexo就2MW7141 项目相关在全球范围的独家开发、生产和商业化以及其他方式开发许可产品的权利。交易金额：迈威生 物将从Kalexo获得最高可达10亿美元的预付款和里程碑付款，以及低个位数的特许权使用费，其中包括 一次性、不可返还的首付款及近端付款1，200万美元现金，作为对价的一部分，迈威生物将在符合约定 条件下另外获得Kalexo总计双位数的A轮优先股。根据有关规定，公司本次交易事项已经第二届董事会 第二十二次会议审议通过，无需提交股东大会审议。 （文章来源：证券日报） ...

迈威生物(688062.SH)发布公告，公司与Kalexo Bio,Inc.公司(以下简称"Kalexo")就2MW7141项目相关(以 下简称"许可产品")签署《独家许可协议》(以下简称"许可协议")及《优先股股权购买协议》。 根据许可协议和股权购买协议，迈威生物许可Kalexo就2MW7141项目相关在全球范围的独家开发、生 产和商业化以及其他方式开发许可产品的权利。交易金额：迈威生物将从Kalexo获得最高可达10亿美元 的预付款和里程碑付款，以及低个位数的特许权使用费，其中包括一次性、不可返还的首付款及近端付 款1,200万美元现金，作为对价的一部分，迈威生物将在符合约定条件下另外获得Kalexo总计双位数的A 轮优先股。 ...

根据许可协议和股权购买协议，迈威生物许可Kalexo就2MW7141项目相关在全球范围的独家开发、生 产和商业化以及其他方式开发许可产品的权利。交易金额：迈威生物将从Kalexo获得最高可达10亿美元 的预付款和里程碑付款，以及低个位数的特许权使用费，其中包括一次性、不可返还的首付款及近端付 款 1,200 万美元现金，作为对价的一部分，迈威生物将在符合约定条件下另外获得 Kalexo 总计双位数 的A轮优先股。 智通财经APP讯，迈威生物(688062.SH)发布公告，公司与Kalexo Bio, Inc.公司(以下简称"Kalexo")就 2MW7141项目相关(以下简称"许可产品")签署《独家许可协议》(以下简称"许可协议")及《优先股股权 购买协议》。 ...

公告显示，根据许可协议和股权购买协议，迈威生物许可Kalexo就2MW7141项目相关在全球范围的独 家开发、生产和商业化以及其他方式开发许可产品的权利。迈威生物将从Kalexo获得最高可达10亿美元 的预付款和里程碑付款，以及低个位数的特许权使用费，其中包括一次性、不可返还的首付款及近端付 款1200万美元现金，作为对价的一部分，迈威生物将在符合约定条件下另外获得Kalexo总计双位数的A 轮优先股。 北京商报讯（记者 丁宁）9月17日晚间，迈威生物（688062）发布公告称，公司与Kalexo Bio, Inc.公司 （以下简称"Kalexo"）就2MW7141项目相关签署《独家许可协议》及《优先股股权购买协议》。 ...

Group 1 - Ping An Insurance has completed the purchase of 74.615 million H-shares through the secondary market as part of its 2025 long-term service plan, accounting for 0.412% of the total share capital, with a total transaction amount of 3.875 billion yuan and an average transaction price of approximately 51.87 yuan per share [1] - The plan involves 83,024 core talents voluntarily participating, with board members, supervisors, and senior management holding 2.52% of the shares, while other employees hold 97.48% [1] Group 2 - Maiwei Biotech has signed an exclusive licensing agreement with Kalexo for the 2MW7141 project, which could yield up to 1 billion USD in upfront and milestone payments, along with low single-digit royalties [2] - The agreement includes a non-refundable upfront payment of 12 million USD and potential equity in Kalexo, with the 2MW7141 drug targeting lipid regulation and prevention of high-risk cardiovascular events [2] Group 3 - Pingzhi Information has been selected as a candidate for a 169.92 million yuan AI computing power technology service project, currently in the candidate public announcement period [3] - The company has disclosed four instances of bidding or pre-bidding for computing power projects in 2025, totaling 362 million yuan in signed contracts [3] Group 4 - Tianpu Co. announced that its stock will resume trading on September 18, 2025, after a period of significant price increase, with uncertainties regarding the change in control of the company [4] - The company has not identified any need for corrections or supplements to previously disclosed information [4] Group 5 - Haoshi Electromechanical announced that director Xiao Yonglin plans to reduce his holdings by up to 290,000 shares, representing 0.09% of the total share capital, for personal financial arrangements [5] - The reduction will be conducted through centralized bidding or block trading, with the price determined by market conditions [5] Group 6 - Xingye Technology has signed a strategic cooperation agreement with Suzhou Nengda to jointly develop flexible electronic skin based on natural leather and bio-based materials [6][7] - The collaboration aims to combine sensor technology with natural and environmentally friendly materials for applications in various emerging industries [6][7] Group 7 - Zhiming Technology is planning a change in control, leading to a temporary suspension of its stock trading starting September 18, 2025, to ensure fair information disclosure [8] - The suspension is expected to last no more than two trading days [8] Group 8 - Zhifei Biological has received approval to conduct clinical trials for its CA111 injection in overweight or obese adults, which is a dual agonist targeting GIP and GLP-1 receptors [9] - The drug has significant market potential in diabetes and weight management [9] Group 9 - Huahai Pharmaceutical's subsidiary has received FDA approval to conduct Phase I clinical trials for HB0043, a bispecific antibody for treating autoimmune diseases [10] - The drug represents a breakthrough in targeting IL-17A and IL-36R, with significant investment already made in its development [10] Group 10 - Top Group's actual controllers have terminated their share reduction plan early, having collectively reduced 3.4936 million shares, or 0.2010% of total shares [11] - The reduction was primarily due to personal funding needs being met [11] Group 11 - Heng Rui Pharmaceutical's injection for breast cancer treatment has had its new indication application accepted and prioritized for review by the National Medical Products Administration [12] - The drug is already approved for use in other cancer treatments, indicating its expanding therapeutic applications [12] Group 12 - China Resources Sanjiu plans to invest up to 10 billion yuan of its own funds in bank wealth management products, with funds being available for rolling use [13] Group 13 - Anke Biotechnology's affiliate has received approval for a key Phase II clinical trial for PA3-17 injection, the first CAR-T cell therapy targeting CD7 to gain such approval [14] - This product is aimed at treating adult relapsed and refractory CD7-positive hematological malignancies [14] Group 14 - Xinhang New Materials' controlling shareholder plans to reduce holdings by up to 2% of the company's shares, totaling approximately 3.4976 million shares [15] Group 15 - Changchun High-tech has reached a cooperation agreement with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy products in China [16][17] - The collaboration includes exclusive rights to three products developed by ALK, enhancing the company's portfolio in allergy treatment [16][17]

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 2025 年度持续督导半年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：迈威生物 | | --- | --- | | 保荐代表人姓名：王永杰、陈新军 | 被保荐公司代码：688062 | 重大事项提示 2025 年上半年，迈威（上海）生物科技股份有限公司（以下简称"上市公 司"、"公司"或"发行人"）归属于上市公司股东的净利润为-55,131.91 万元， 归属于母公司所有者的扣除非经常性损益的净利润为-57,353.90 万元，尚未实现 盈利。 公司作为一家创新型生物医药企业，随着新药研发管线持续推进，多个创新 药物处于关键临床试验研究阶段，整体研发投入仍维持在较高水平。截至本报告 披露日，公司拥有 14 个处于临床前、临床或上市阶段的重点品种，包括 10 个创 新药，4 个生物类似药，专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领 域。其中，已上市品种 4 个，提交上市许可申请准备阶段的品种 1 个，处于 III 期关键注册临床阶段品种 2 个，以及处于其他不同临床、临床前阶段的品种。 2025 年上半年，公司 ...